ICC International Cannabis Corp. to Supply New Zealand’s NUBU Pharmaceuticals with Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products
Jul 18 19
ICC International Cannabis Corp. announced that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Under the terms of the Agreement, ICC will supply NUBU will a suite of full-spectrum pharmaceutical grade medical cannabis products including: Packaged and labelled medical cannabis including; oil/tincture and capsules in finished goods form. ICC Branded, co-branded and/or ICC labelled medical cannabis products under development including but not limited to: Cannabis oil; Capsules; Transdermal patches; Oral sprays; Inhalers; and Vaporizing cartridges. Hemp derived CBD adhering to the international standard of less than 0.3% THC, in both bulk form (i.e. CBD isolate, CBD distillate, full spectrum oil) and finished good forms. ICC will leverage its existing brand portfolio, European GMP-certified processing facilities and extraction ready inventories to maximize margins and profitability, while servicing New Zealand’s high value patient population. The Company remains committed to servicing all links of the cannabis value chain including the manufacture and export of finished product to developing international marketplaces.
Icc International Cannabis Corp. Reports Earnings Results for the Full Year Ended February 28, 2019
Jun 28 19
ICC International Cannabis Corp. announced earnings results for the full year ended February 28, 2019. For the full year, the company announced net loss was CAD 60.309 million compared to CAD 988,900 a year ago. Basic loss per share from continuing operations was CAD 0.37 compared to CAD 0.06 a year ago.
International Cannabis Completes Technical Feasibility Study for Danish Gacp/Eu-Gmp Certified Greenfield Cultivation and Processing Facility
Jun 18 19
ICC International Cannabis Corp. announced that the company has completed aTechnical Feasibility Study (the “Feasibility Study”) relating to its proposed 150,000 square foot Danish GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility (the “Danish Facility”). The Company previously engaged a leading Denmark based international pharma engineering firm to perform a comprehensive Feasibility Study for its planned Danish Facility; situated on a 100-acre land parcel in Møldrup, Denmark. The initiation of the Danish Facility project marks another milestone for ICC, as it continues to execute on its long-term economically sustainable and alpha generating corporate stratagem. Leveraging proprietary design and build IP, as well as its proven cultivation methodologies, ICC seeks to achieve full optimization of each square foot in the Danish Facility. The Company forecasts that further engineering efficiencies will be achieved by way of customized process design and building systems. Initial conclusions of the Feasibility Study indicate that once fully operational, ICC’s Danish Facility will achieve annualized production capabilities of circa 20,000,000 grams of artisanal grown, ultra-premium dried cannabis flower for sale into high value medical markets. International Cannabis also plans to pursue the outdoor cultivation of high quality, low cost field crops on 45 acres of farmable land. Preliminary soil sampling initiatives of the Company’s Danish land package has indicated ideal soil composition and health. With increased organic matter levels as a result of implementing its outdoor agricultural program, ICC is forecasted to yield 81,000 kg dried cannabis in the 2020 harvest season from its of auto-flower and photoperiod cannabis crops. The scope of the Feasibility Study included an exhaustive analysis of EU-GMP regulations/requirements, initial environmental studies/samplings, the development of facility specific standard operating guidelines and processing schedules, as well as the delivery of: Domestic and international compliance statements; Project profitability assessment and economic models; Detailed capital and operating expenditure estimates; Itemized process work flows; General engineering and building principles; Project milestone timelines; and, Macro risk assessment and Recommendations. International Cannabis’ Danish Facility will be constructed in four portioned blocks, leveraging modular designs that are architected to support streamlined future expansion. The standalone, single level Danish Facility will be comprised of a 150,000 square foot structural footprint and will include the following design specifications: Cultivation block; 20,000 square feet of office/adminisNNO G tration, gowning and utilities space; GMP compliant waste disposal area; Segregated Good Distribution Practices loading bays; Proprietary Building Management Systems, Facility Monitoring Systems and Quality Management Systems (“QMS”); Apportioned GACP and EU-GMP areas, including air locked access corridors; and, Internal service road; To expedite construction timelines while maintaining a critical project path, International Cannabis intends to simultaneously build out each respective modular block. The Company is also presently running capacity simulation scenarios to further refine cost estimations, while optimizing production, processing, manufacturing and distribution work flows. The completion of 150,000 Danish Facility on time and within budget, will signal to the marketplace that ICC has established yet another cultivation and manufacturing hub; enabling the distribution of high-margin products into high-value European patient populations with drastically shorter lead times. Throughout production ICC intends to leverage various cultivation and plant physiology concepts with the objective of optimizing plant performance and thereby achieving greater production yields. The Company’s cultivation concepts have been developed over five years of Canadian commercial cultivation experience and include: Proprietary soil/nutrient monitoring and plant health monitoring solutions; Consistent delivery of ideal primary, secondary, and micro nutrients; Evaluation and comprehension of the rhizosphere and its effect on inputs and yield; Creation of crops that are more resistant to pests and disease; Manipulation of nutrient and substrate conditions to drive plant health and yield; and, Deploying solutions to influence biochemical and physiological pathways toward superior quality and yield.